Childhood growth hormone treatment: challenges, opportunities, and considerations

被引:0
|
作者
Tidblad, Anders [1 ,2 ]
Savendahl, Lars [1 ,2 ]
机构
[1] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
[2] Karolinska Univ Hosp, Div Paediat Endocrinol, S-17176 Stockholm, Sweden
来源
LANCET CHILD & ADOLESCENT HEALTH | 2024年 / 8卷 / 08期
基金
瑞典研究理事会;
关键词
LONG-TERM MORTALITY; PRADER-WILLI-SYNDROME; FOR-GESTATIONAL-AGE; NOONAN SYNDROME; SHORT STATURE; CANCER INCIDENCE; FACTOR-I; CHILDREN; DEFICIENCY; RISK;
D O I
10.1016/S2352-4642(24)00127-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
With long standing demand and popularity, growth hormone treatments continue to be a topic of interest for paediatric endocrinologists and general paediatricians due to ongoing issues regarding their long-term effects, the safety of childhood treatment, and the introduction of long-acting growth hormone preparations in the past decade. Moreover, uncertainty regarding how to approach individual patients and their treatment indications remains, particularly concerning tailored treatment goals and objectives; this uncertainty is further complicated by the multitude of approved indications that surpass substitution therapy. The paediatric endocrinologist thus grapples with pertinent questions, such as what defines reasonable treatment goals for each individual given their indications, and when (and how) to initiate the necessary discussions about risks and benefits with patients and their families. The aim of this Review is to offer advanced physiological concepts of growth hormone function, map out approved paediatric indications for treatment along with evidence on their effects and safety, highlight controversies and complexities surrounding childhood growth hormone treatment, and discuss the potential of long-acting growth hormone and future directions in the realm of childhood growth hormone treatment.
引用
收藏
页码:600 / 610
页数:11
相关论文
共 50 条
  • [1] Growth hormone: Challenges and opportunities for the biotechnology sector
    Hathaway, DR
    [J]. JOURNAL OF ANTI-AGING MEDICINE, 2002, 5 (01): : 57 - 62
  • [2] Monitoring growth hormone treatment: Safety considerations
    Blethen, SL
    [J]. ENDOCRINOLOGIST, 1996, 6 (05): : 369 - 374
  • [3] Global Micronutrient Deficiencies in Childhood and Impact on Growth and Survival: Challenges and Opportunities
    Imdad, Aamer
    Bhutta, Zulfiqar A.
    [J]. MEETING MICRONUTRIENT REQUIREMENTS FOR HEALTH AND DEVELOPMENT, 2012, 70 : 1 - 10
  • [4] Growth and growth hormone status following treatment for childhood leukaemia
    Shalet, SM
    Brennan, BMD
    [J]. HORMONE RESEARCH, 1998, 50 (01) : 1 - 10
  • [5] Childhood growth hormone treatment associated with cardiovascular disease
    Isaacs, David
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2021, 57 (08) : 1341 - 1342
  • [6] Treatment of childhood growth hormone deficiency: Efficacy and innovation
    Cuttler, L
    [J]. THERAPEUTIC OUTCOME OF ENDOCRINE DISORDERS: EFFICACY, INNOVATION AND QUALITY OF LIFE, 2000, : 30 - 37
  • [7] Safety of growth hormone after treatment of a childhood malignancy
    OgilvyStuart, AL
    [J]. HORMONE RESEARCH, 1995, 44 : 73 - 79
  • [8] Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors
    Pollock, Netanya I.
    Cohen, Laurie E.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [9] Childhood Disorders of the Synapse: Challenges and Opportunities
    Hughes, Virginia
    Sheng, Morgan
    Zoghbi, Huda
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (152)
  • [10] Childhood Obesity in the Pacific: Challenges and Opportunities
    Amerita Ravuvu
    Gade Waqa
    [J]. Current Obesity Reports, 2020, 9 : 462 - 469